SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 21, 2003; DOI 10.1182/blood-2003-04-1010. This Article Full Text (PDF) All Versions of this Article: 2003-04-1010v1 102/13/4298    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gardembas, M. Articles by Guilhot, F. Search for Related Content PubMed PubMed Citation Articles by Gardembas, M. Articles by Guilhot, F. Social Bookmarking                   What's this? Submitted April 2, 2003 Accepted August 10, 2003 Results of a prospective phase II study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukaemia patients in chronic phase Martine Gardembas, Philippe Rousselot, Michel Tulliez, Magda Vigier, Agnes Buzyn, Francoise Rigal-Huguet, Laurence Legros, Mauricette Michallet, Christian Berthou, Nathalie Cheron, Frederic Maloisel, Francois Xavier Mahon, Thierry Facon, Patrice Berthaud, Joelle Guilhot, and Francois Guilhot* Hematology, University Hospital, Angers, France Hematology, University Hospital, Paris, Saint-Louis, France Hematology, University Hospital, Paris, Creteil, France Hematology, University Hospital, Nantes, France Hematology, University Hospital, Paris, Necker, France Hematology, University Hospital, Toulouse, France Hematology, University Hospital, Nice, France Hematology, University Hospital, Lyon, France Hematology, University Hospital, Brest, France Hematology, University Hospital, Paris, Saint-Antoine, France Hematology, University Hospital, Strasbourg, France Hematology, University Hospital, Bordeaux, France Hematology, University Hospital, Lille, France Unite Oncologie, Novartis Pharma, Rueil-Malmaison, France Oncology Hematology and Cell Therapy, University Hospital, Poitiers, France * Corresponding author; email: f.guilhot{at}chu-poitiers.fr. In Chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent alone high rate of cytogenetic responses were recorded. However several mechanisms of resistance have been described. In vitro studies examining the effects of imatinib mesylate plus cytarabine have shown synergistic anti-proliferative effects of this combination. Thus the CML French Group decided to perform a phase II trial testing a combination of imatinib mesylate and low dose cytarabine for 30 previously untreated patients in chronic phase. Treatment was administered on 28 days cycles. Patients were treated continuously with imatinib mesylate orally at a dose of 400 mg daily. Cytarabine was given on days 15-28 of each cycle at an initial dose of 20 mg/m2/day via subcutaneous injection. Adverse events were frequently observed with grade 3 or 4 hematologic toxicities and non hematologic toxicities in 53% (n=16) and in 23% (n= 7) of patients respectively. The cumulative incidence of complete cytogenetic response (CCR) at 12 months was 83% and at 6 months 100% of the patients achieved complete hematologic response (CHR) . We concluded that the combination was safe and promising given the high rate of responses. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. E. Cortes Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now? J. Clin. Oncol., July 10, 2008; 26(20): 3308 - 3309. [Full Text] [PDF] W. Deenik, B. van der Holt, G. E. G. Verhoef, W. M. Smit, M. J. Kersten, H. C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A. V. M. B. Schattenberg, J. J. W. M. Janssen, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia Blood, March 1, 2008; 111(5): 2581 - 2588. [Abstract] [Full Text] [PDF] A. Zeuner, M. Signore, D. Martinetti, M. Bartucci, C. Peschle, and R. De Maria Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor Cancer Res., May 15, 2007; 67(10): 4767 - 4773. [Abstract] [Full Text] [PDF] S. Balabanov, A. Gontarewicz, P. Ziegler, U. Hartmann, W. Kammer, M. Copland, U. Brassat, M. Priemer, I. Hauber, T. Wilhelm, et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach Blood, February 15, 2007; 109(4): 1701 - 1711. [Abstract] [Full Text] [PDF] M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF] L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B. J. Druker, R. A. Larson, S. O'Brien, C. So, G. Massimini, and F. Guilhot Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials Blood, September 1, 2006; 108(5): 1478 - 1484. [Abstract] [Full Text] [PDF] T. O'Hare, D. K. Walters, E. P. Stoffregen, D. W. Sherbenou, M. C. Heinrich, M. W.N. Deininger, and B. J. Druker Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib Clin. Cancer Res., October 1, 2005; 11(19): 6987 - 6993. [Abstract] [Full Text] [PDF] F. Millot, P. Traore, J. Guilhot, B. Nelken, T. Leblanc, G. Leverger, D. Plantaz, Y. Bertrand, P. Bordigoni, and F. Guilhot Clinical and Biological Features at Diagnosis in 40 Children With Chronic Myeloid Leukemia Pediatrics, July 1, 2005; 116(1): 140 - 143. [Abstract] [Full Text] [PDF] A. L. Dewar, A. C. Cambareri, A. C. W. Zannettino, B. L. Miller, K. V. Doherty, T. P. Hughes, and A. B. Lyons Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood, April 15, 2005; 105(8): 3127 - 3132. [Abstract] [Full Text] [PDF] M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF] M. W.N. Deininger Management of Early Stage Disease Hematology, January 1, 2005; 2005(1): 174 - 182. [Abstract] [Full Text] [PDF] M. Baccarani, G. Martinelli, G. Rosti, E. Trabacchi, N. Testoni, S. Bassi, M. Amabile, S. Soverini, F. Castagnetti, D. Cilloni, et al. Imatinib and pegylated human recombinant interferon-{alpha}2b in early chronic-phase chronic myeloid leukemia Blood, December 15, 2004; 104(13): 4245 - 4251. [Abstract] [Full Text] [PDF] M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells Blood, September 1, 2004; 104(5): 1442 - 1449. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020